文献速递膀胱癌与上尿路尿路上皮癌

提高膀胱癌原位癌检出:尿细胞学与Xpert® BC Monitor的对比

Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.
PubMed 文献 · BJU Int · 2024-05-08

这项前瞻性多中心研究在2018年7月至2020年12月于六家德国大学中心纳入733例拟行经尿道膀胱肿瘤电切术的患者,比较尿细胞学与Xpert BC Monitor检测膀胱癌的性能。总体敏感度尿细胞学39%对Xpert BC Monitor 75%,原位癌患者中分别为59%对90%;Xpert BC Monitor在孤立性原位癌中漏诊4例肿瘤(阴性预测值98%)。

要点

  • 总体敏感度尿细胞学39%对Xpert BC Monitor 75%,特异度93%对69%。
  • 原位癌患者中敏感度尿细胞学59%对Xpert BC Monitor 90%。
  • 孤立性原位癌中Xpert BC Monitor漏诊4例肿瘤,阴性预测值98%。

核心结论

  • 尿细胞学阳性可能提示膀胱癌,应认真对待。
  • Xpert BC Monitor可能是有用的诊断工具,用于正确识别孤立性原位癌且膀胱镜检查无异常或结论不明确的患者。

研究设计与样本

  • 前瞻性多中心研究,2018年7月至2020年12月在六家德国大学中心筛查756例拟行经尿道膀胱肿瘤电切术的患者。
  • 共纳入733例患者(568例男性[78%];中位[四分位距]年龄72[62-79]岁),其中482例(65.8%)存在膀胱癌,258例(53.5%)为高级别肿瘤。
  • 在经尿道膀胱肿瘤电切术前进行中心尿细胞学和Xpert BC Monitor检测。
  • 采用McNemar检验对尿细胞学与Xpert BC Monitor进行统计学比较。

主要发现

  • 总体敏感度、特异度、阴性预测值和阳性预测值:尿细胞学分别为39%、93%、44%和92%;Xpert BC Monitor分别为75%、69%、59%和82%。
  • 原位癌(伴发或孤立)患者中敏感度、特异度、阴性预测值和阳性预测值:尿细胞学分别为59%、93%、87%和50%;Xpert BC Monitor分别为90%、69%、95%和50%。
  • 在孤立性原位癌患者中,Xpert BC Monitor漏诊4例肿瘤(阴性预测值98%)。
  • 在膀胱镜检查结论不明确或阴性且Xpert结果阴性的情况下,Xpert BC Monitor可能避免63.3%的经尿道膀胱肿瘤电切术。

临床怎么用

  • 尿细胞学阳性可能提示膀胱癌,应认真对待。
  • Xpert BC Monitor可能是有用的诊断工具,用于正确识别孤立性原位癌且膀胱镜检查无异常或结论不明确的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate and compare the performance of urinary cytology and the Xpert BC Monitor test in the detection of bladder cancer in various clinically significant patient cohorts, including patients with carcinoma in situ (CIS), in a prospective multicentre setting, aiming to identify potential applications in clinical practice. PATIENTS AND METHODS: A total of 756 patients scheduled for transurethral resection of bladder tumour (TURBT) were prospectively screened between July 2018 and December 2020 at six German University Centres. Central urinary cytology and Xpert BC Monitor tests were performed prior to TURBT. The diagnostic performance of urinary cytology and the Xpert BC Monitor was evaluated according to sensitivity (SN), specificity (SC), negative predictive value (NPV) and positive predictive value (PPV). Statistical comparison of urinary cytology and the Xpert BC Monitor was conducted using the McNemar test. RESULTS: Of 756 screened patients, 733 (568 male [78%]; median [interquartile range] age 72 [62-79] years) were included. Bladder cancer was present in 482 patients (65.8%) with 258 (53.5%) high-grade tumours. Overall SN, SC, NPV and PPV were 39%, 93%, 44% and 92% for urinary cytology, and 75%, 69%, 59% and 82% for the Xpert BC Monitor. In patients with CIS (concomitant or solitary), SN, SC, NPV and PPV were 59%, 93%, 87% and 50% for urinary cytology, and 90%, 69%, 95% and 50% for the Xpert BC Monitor. The Xpert BC Monitor missed four tumours (NPV = 98%) in patients with solitary CIS, while potentially avoiding 63.3% of TURBTs in inconclusive or negative cystoscopy and a negative Xpert result. CONCLUSION: Positive urinary cytology may indicate bladder cancer and should be taken seriously. The Xpert BC Monitor may represent a useful diagnostic tool for correctly identifying patients with solitary CIS and unsuspicious or inconclusive cystoscopy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Haas M, Kriegmair MC, Breyer J, et al. Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor. BJU Int. 2024. PMID: 38717014. doi:10.1111/bju.16389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。